Fanny Senner, Lena Hiendl, Susanne Bengesser, Kristina Adorjan, Ion-George Anghelescu, Bernhardt T Baune, Monika Budde, Udo Dannlowski, Detlef E Dietrich, Peter Falkai, Andreas J Fallgatter, Alkomiet Hasan, Maria Heilbronner, Markus Jäger, Georg Juckel, Janos L Kalman, Carsten Konrad, Mojtaba Oraki Kohshour, Sergi Papiol, Daniela Reich-Erkelenz, Jens Reimer, Sabrina K Schaupp, Max Schmauß, Simon Senner, Carsten Spitzer, Thomas Vogl, Jörg Zimmermann, Urs Heilbronner, Eva C Schulte, Thomas G Schulze, Eva Z Reininghaus, Sophie-Kathrin Kirchner, Nina Dalkner
Existing guidelines recommend psychopharmacological treatment for the management of schizophrenia and bipolar disorder as part of holistic treatment concepts. About half of the patients do not take their medication regularly, although treatment adherence can prevent exacerbations and re-hospitalizations. To date, the relationship between medication adherence and cognitive performance is understudied. Therefore, this study investigated the relationship between medication adherence and cognitive performance by analyzing the data of 862 participants with schizophrenia-spectrum and bipolar disorders (mean [SD] age, 41...
March 25, 2023: Translational Psychiatry
Scott R Beach, James Luccarelli, Nathan Praschan, Mark Fusunyan, Gregory L Fricchione
Catatonia occurs secondary to both primary psychiatric and neuromedical etiologies. Emerging evidence suggests possible linkages between causes of catatonia and neuroinflammation. These include obvious infectious and inflammatory etiologies, common neuromedical illnesses such as delirium, and psychiatric entities such as depression and autism-spectrum disorders. Symptoms of sickness behavior, thought to be a downstream effect of the cytokine response, are common in many of these etiologies and overlap significantly with symptoms of catatonia...
March 23, 2023: Schizophrenia Research
Ta-Chuan Yeh, Mu-Hong Chen, Ya-Mei Bai, Shih-Jen Tsai, Ju-Wei Hsu, Kai-Lin Huang, Tung-Ping Su, Tzeng-Ji Chen, Chih-Sung Liang
BACKGROUND: The mental health of children and adolescents with autism spectrum disorder (ASD) is a concern of recent years. However, a large-scale longitudinal study investigating the risk and the time course of subsequent psychiatric comorbidities is still lacking. METHODS: Using the Taiwan National Health Insurance Research Database, 13,382 children and adolescents with ASD, and 53,528 age- and sex-matched non-ASD controls were enrolled between 2001 and 2009, and followed to the end of 2011...
March 23, 2023: Journal of Affective Disorders
Ana Montoya, Katherine Wen, Jasmine L Travers, Maricruz Rivera-Hernandez, Elizabeth White, Vincent Mor, Sarah D Berry
OBJECTIVE: To examine incidence of and resident characteristics associated with breakthrough infections (BTIs) and severe illness among residents with 2 messenger RNA (mRNA) vaccinations. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: Nursing home (NH) residents who completed their primary series of mRNA COVID-19 vaccination by March 31, 2021. METHODS: Electronic health records and Minimum Data Set assessments from a multistate NH data consortium were used to identify BTI and severe illness (a composite measure of hospitalization and/or death within 30 days of BTI) occurring prior to November 24, 2021...
March 2, 2023: Journal of the American Medical Directors Association
Li-Jun Wang, Tian-Hua Cheng, Jia-Sen Geng, Juan Yang, Chang Liu, Guo-Hui Zhu, Jia-Cheng Luo, Gui-Zhen Wang, Xiang He Zhu, Yi Wang, Jia Huang, Yan-Yu Wang
BACKGROUND: Previous studies have found that patients with schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BD) all have facial emotion recognition deficits, but the differences and similarities of these deficits in the three groups of patients under different social interaction situations are not clear. The present study aims to compare the ability of facial emotion recognition in three different conversation situations from a cross-diagnostic perspective. METHODS: Thirty-three participants with SCZ, 35 participants with MDD, and 30 participants with BD were recruited, along with 31 healthy controls...
March 21, 2023: Asian Journal of Psychiatry
Agurne Sampedro, Naroa Ibarretxe-Bilbao, Javier Peña, Alberto Cabrera-Zubizarreta, Pedro Sánchez, Ainara Gómez-Gastiasoro, Nagore Iriarte-Yoller, Cristóbal Pavón, Mikel Tous-Espelosin, Natalia Ojeda
Cognitive remediation has been shown to improve cognition in schizophrenia, but little is known about the specific functional and structural brain changes related to the implementation of an integrative cognitive remediation program. This study analyzed the functional and structural brain changes identified after implementing an integrative cognitive remediation program, REHACOP, in schizophrenia. The program combined cognitive remediation, social cognitive training, and functional and social skills training...
March 23, 2023: Schizophrenia Research
Lusi Zhang, Paulo Lizano, Yanxun Xu, Leah H Rubin, Adam M Lee, Rebekka Lencer, James L Reilly, Richard S E Keefe, Sarah K Keedy, Godfrey D Pearlson, Brett A Clementz, Matcheri S Keshavan, Elliot S Gershon, Carol A Tamminga, John A Sweeney, S Kristian Hill, Jeffrey R Bishop
Elevated markers of peripheral inflammation are common in psychosis spectrum disorders and have been associated with brain anatomy, pathology, and physiology as well as clinical outcomes. Preliminary evidence suggests a link between inflammatory cytokines and C-reactive protein (CRP) with generalized cognitive impairments in a subgroup of individuals with psychosis. Whether these patients with elevated peripheral inflammation demonstrate deficits in specific cognitive domains remains unclear. To examine this, seventeen neuropsychological and sensorimotor tasks and thirteen peripheral inflammatory and microvascular markers were quantified in a subset of B-SNIP consortium participants (129 psychosis, 55 healthy controls)...
March 23, 2023: Schizophrenia Research
Konasale Prasad, Jonathan Rubin, Satish Iyengar, Joshua Cape
No abstract text is available yet for this article.
March 23, 2023: Schizophrenia Research
Zhuyun Li, Ying Qing, Gaoping Cui, Minghui Li, Tiantian Liu, Yanyan Zeng, Chao Zhou, Xiaowen Hu, Jie Jiang, Dandan Wang, Yan Gao, Juan Zhang, Changqun Cai, Tao Wang, Chunling Wan
Evidence has shown that the gut microbiota is closely related to the pathogenesis of schizophrenia, but temporal changes in the gut microbiota of patients with schizophrenia (SZ) during treatment remain unclear. Here, to evaluate temporal changes in the gut microbiota in schizophrenia, we performed whole-genome shotgun metagenomics on fecal samples from 36 healthy controls (HCs) and 19 baseline-period patients, and followed up with patients upon treatment. Compared to that in HCs, beta diversity in SZ was significantly distinct...
March 23, 2023: Schizophrenia Research
Jorge A Sanchez Ruiz, Brandon J Coombes, Richard S Pendegraft, Aysegul Ozerdem, Susan L McElroy, Alfredo B Cuellar-Barboza, Miguel L Prieto, Mark A Frye, Stacey J Winham, Joanna M Biernacka
Individuals with bipolar disorder (BD) require chronic pharmacotherapy, typically including medication switches or polypharmacy due to persisting symptoms or intolerable side effects. Here, we quantified pharmacotherapy exposure (PE) of Mayo Clinic BD Biobank participants using the number of cross-sectional (at enrollment) and lifetime BD-specific medications and medication classes, to understand the relationship between PE and markers of disease severity or treatment failure, psychiatric comorbidities, and polygenic risk scores (PRS) for six major psychiatric disorders...
March 21, 2023: Psychiatry Research
Chiu-Yueh Hsiao, Ming-Hong Hsieh, Feng-Chin Chung, Shu-Chuan Chiu, Chi-Wen Chang, Yun-Fang Tsai
INTRODUCTION: Family functioning, particularly among primary family caregivers for patients with schizophrenia, is a global concern that poses unprecedented challenges. The family unit is a pivotal agent for the preservation of the integrity of individual members. Little attention has been paid to the changes in family functioning and their predictors in primary family caregivers. This study aimed to examine the changes in and the correlates of family functioning in primary family caregivers of individuals with schizophrenia over a 6-month post-discharge period...
March 25, 2023: Journal of Nursing Scholarship
Isabel Zbukvic, Shayden Bryce, Joanna Moullin, Kelly Allott
For people living with psychosis, cognitive impairment is common and can have significant impacts for functional recovery, impacting engagement with treatment and quality of life more broadly. There is now strong evidence for the effectiveness of cognition-focused treatments, such as cognitive remediation to improve clinical and functional outcomes for people with psychosis. However, engagement with treatment has been a long-standing issue in mental health care, including for people with psychosis, who often experience difficulties with motivation...
March 25, 2023: Australian and New Zealand Journal of Psychiatry
Leah M Fleming, Ann Catherine Lemonde, David Benrimoh, James M Gold, Jane R Taylor, Ashok Malla, Ridha Joober, Srividya N Iyer, Martin Lepage, Jai Shah, Philip R Corlett
Psychotic disorders are highly heterogeneous. Understanding relationships between symptoms will be relevant to their underlying pathophysiology. We apply dimensionality-reduction methods across two unique samples to characterize the patterns of symptom organization. We analyzed publicly-available data from 153 participants diagnosed with schizophrenia or schizoaffective disorder (fBIRN Data Repository and the Consortium for Neuropsychiatric Phenomics), as well as 636 first-episode psychosis (FEP) participants from the Prevention and Early Intervention Program for Psychosis (PEPP-Montreal)...
March 24, 2023: Scientific Reports
Shih-Kuang Chiang, Jia-Rong Jhong, Chia-Yu Wang
PURPOSE: This study investigates whether using group Cognitive Stimulation Therapy (CST) effectively improves functioning among middle-aged and elderly patients with chronic schizophrenia and a below-normal cognitive range. METHODS: The study included an experimental group (N Z 24), which was divided into two sub-groups to receive group CST, and a control group (N Z 24), who received treatment as usual (TAU). We assessed cognitive functions using the Mini-Mental Status Examination (MMSE)...
March 22, 2023: Journal of the Formosan Medical Association
Anup Das, Vinod Menon
Electrical stimulation of the medial temporal lobe (MTL) has the potential to uncover causal circuit mechanisms underlying memory function. However, little is known about how MTL stimulation alters information flow with frontoparietal cortical regions implicated in episodic memory. We used intracranial electroencephalography recordings from humans (14 participants, 10 females) to investigate how MTL stimulation alters directed information flow between MTL and prefrontal cortex (PFC) and between MTL and posterior parietal cortex (PPC)...
March 24, 2023: Journal of Neuroscience
Éimear M Foley, Sian Lowri Griffiths, Alexander Murray, Jack Rogers, Fabiana Corsi-Zuelli, Hannah Hickinbotham, Ella Warwick, Martin Wilson, Muzaffer Kaser, Graham K Murray, Bill Deakin, Deepak Jadon, John Suckling, Nicholas M Barnes, Rachel Upthegrove, Golam M Khandaker
INTRODUCTION: Evidence suggests a potentially causal role of interleukin 6 (IL-6), a pleiotropic cytokine that generally promotes inflammation, in the pathogenesis of psychosis. However, no interventional studies in patients with psychosis, stratified using inflammatory markers, have been conducted to assess the therapeutic potential of targeting IL-6 in psychosis and to elucidate potential mechanism of effect. Tocilizumab is a humanised monoclonal antibody targeting the IL-6 receptor to inhibit IL-6 signalling, licensed in the UK for treatment of rheumatoid arthritis...
March 24, 2023: BMJ Open
André J Scheen
Psychotropic drugs may be associated with metabolic disorders, often but not only triggered by weight gain. Disorders include dysglycemia and diabetes, atherogenic dyslipidemia and metabolic syndrome. Overall, metabolic risk is lower with antidepressants than with antipsychotics. Among antidepressants, metabolic disorders may occur with both selective serotonin reuptake inhibitors and tricyclics, but with some between-molecule differences in each pharmacological family. Among antipsychotics, the risk is higher with second-generation (atypical) than first-generation agents...
March 22, 2023: Annales D'endocrinologie
Alec Buchanan, Elina Stefanovics, Robert Rosenheck
BACKGROUND: People with schizophrenia are frequently victims of violence. Previous attempts to examine the reasons for this have mostly used cross-sectional designs that limit the ability to distinguish, among the correlates they identify, potential causes of victimization from its consequences. METHOD: We studied patients with schizophrenia participating in the NIMH-funded Clinical Antipsychotic Treatment for Intervention Effectiveness (CATIE) trial. The dependent variable was self-reported victimization during the 18-month CATIE follow-up...
March 22, 2023: Schizophrenia Research
Silvia Marcó-García, Georgina Guilera-Ferrer, Marta Ferrer-Quintero, Susana Ochoa, Gemma Escuder-Romeva, Arantxa Martínez-Mondejar, Vanessa Montalbán-Roca, Ana Escanilla-Casal, Francisco Martínez-Zambrano, Sol Balsells-Mejía, Elena Huerta-Ramos
UNLABELLED: Severe mental disorder (SMD) includes people with long-term mental disorders, disability and social dysfunction. The mental capacity evaluation of the people has been a key aspect in legislative systems around the world and different proposals have been made. In countries like Spain, until 2021, the mental capacity of individuals was assessed by means of legal proceedings. In the last years, there has been a notable increase in the number of claims for legal incapacity, but no data are available on the total number of persons with CM, neither on the specific pathologies, or clinical and cognitive profiles...
March 22, 2023: International Journal of Law and Psychiatry
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larsen
BACKGROUND: Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable antipsychotic formulation for gluteal administration every 2 months, currently being investigated for the treatment of schizophrenia and bipolar I disorder (BP-I). The objectives of this trial were to evaluate the safety and tolerability of Ari 2MRTU 960, and the similarity of aripiprazole plasma concentrations following administration of Ari 2MRTU 960 or aripiprazole once-monthly 400 mg (AOM 400), in adults with schizophrenia or BP-I...
March 24, 2023: CNS Drugs
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.